STUTTGART, Germany, MUNICH and PARIS, June 26, 2018 /PRNewswire/ — GAC Motor, China’s fastest-growing auto brand, has successfully concluded its first talent recruitment drive in Europe, hosting three career fairs in Stuttgart, Munich, and Paris that have attracted over 700 applicants from across Europe as the company prepares to expand into more markets around the world.

GAC Motor offers high-end positions available in the areas of vehicle engineering, process and technology, management and marketing. The 700 applicants who attended the recruitment events came from countries across Europe, including Germany, France, the U.K., Spain, Italy, and Belgium, with over 80 percent holding master’s degrees, and many being veterans and experts in their respective fields.

The events also drew representatives from governments, industry, and institutes of higher education who gathered to discuss the development and future of new energy and intelligent manufacturing (IM) in the automotive industry.

“GAC Motor is expanding fast, and we’re excited at the opportunities that we see for further growth in Europe,” said the senior executive of GAC Motor responsible for this recruitment drive. “The GAC Motor brand is already present in 14 countries, and sales have increased by 22.7 percent in the first quarter of 2018. We are only able to achieve such remarkable results because of the excellent work of all of our employees. We believe that we will only be able to compete globally if we have a top-flight, global team, and after the U.S. and Japan, Europe represents the biggest pool of overseas talent.”

Not satisfied with just assembling a global team of top industry talent to advance its product development, manufacturing, branding and marketing capabilities, GAC Motor is emphasizing the training and personal development of its employees by offering competitive compensation packages and giving employees the opportunity to participate in on- and off-the-job training to enhance their skills. The company will encourage and support them in developing new ideas, enabling the company to grow along with them.

Yu Jun, president of GAC Motor, has commented that talent and innovation are the No.1 forces driving the company’s development. GAC Motor will stick to the people-oriented management principle and expand the global talent search to improve the comprehensive strength of the company’s world-leading team.

GAC Motor is moving towards its plan to further expand into global markets by its 10th anniversary. On July 21st, the company will announce the global launch of its new branding concept. Later this year, GAC Motor will participate in the Paris Motor Show and the Moscow International Auto Show, showing to the world the charm and capabilities of the Chinese automotive industry.

About GAC Motor

Founded in 2008, Guangzhou Automobile Group Motor CO., LTD (GAC Motor) is a subsidiary of GAC Group which ranks 238th among the Fortune Global 500 companies. The company develops and manufactures premium quality vehicles, engines, components and auto accessories. GAC Motor has now ranked the first among all Chinese brands for five consecutive years in J.D. Power Asia Pacific’s China Initial Quality Study SM (IQS), demonstrating the company’s quality-centric strategy from innovative research and development (R&D), manufacturing to supply chain, and sales & services.

For more information, please visit:

Facebook: https://www.facebook.com/GACMotor
Instagram: https://www.instagram.com/gac_motor
Twitter: https://www.twitter.com/gac_motor

Media Contact:
Sukie Wong
+86-186-8058-2829
GACMotor@126.com

Photo – https://mma.prnewswire.com/media/710957/GAC.jpg
Photo – https://mma.prnewswire.com/media/710958/career_fair.jpg
Photo – https://mma.prnewswire.com/media/710959/GS8_SUV.jpg

SINGAPORE, June 26, 2018 /PRNewswire/ — Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to market Invossa^®-K in Saudi Arabia and United Arab Emirates. Invossa^®-K is a treatment for osteoarthritis pain with long-term efficacy. The agreement builds on the existing co-promotion agreement between the two companies in Korea signed in April 2017.

First approved by the Korean Ministry of Food and Drug Safety (MFDS) in 2017, the treatment has been hailed as the world’s first cell-mediated gene therapy for osteoarthritis.¹ Invossa^®-K is an intra-articular injection that is non-surgical treatment option, demonstrating sustained pain reduction and functional improvement of articular joint for two years following a single injection in a US phase II clinical trial and one year in a Korean phase III clinical trial.^2,3

Under the terms of the partnership, Mundipharma will be responsible for the marketing and distribution of Invossa^®-K to medical professionals and hospitals in Saudi Arabia and United Arab Emirates.

“We are delighted to extend our relationship with Kolon Life Science and Invossa^®-K internationally,” said Raman Singh, CEO, Mundipharma. “This partnership is a prime example of how our partners can effectively leverage the strength of our network capability and experience to ensure that hospitals, GPs and patients in new markets like Saudi Arabia and United Arab Emirates have access to new breakthrough treatments like Invossa^®-K,” he added.

The Osteoarthritis Research Society International (OARSI) defines osteoarthritis (OA) as ‘a disorder involving movable joints characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses including pro-inflammatory pathways of innate immunity.’⁴

“Mundipharma’s global sales and marketing capability in the area of pain management makes it an ideal partner to establish successful pathways into new markets,” said Woo-Sok Lee, President and CEO, Kolon Life Sciences. “They are an ideal partner to help establish Invossa^®-K in Saudi and UAE markets as we look to scale this breakthrough therapy as a global standard treatment option.”

®: INVOSSA is a Registered Trademark in Korea of Kolon TissueGene, Inc.

About Invossa^®-K

Invossa^®-K is composed of a 3:1 mixture of normal human chondrocytes (hChonJ) and human chondrocytes transduced with the human TGF-β1 gene (hChonJb#7). The hChonJb#7 cells are irradiated prior to dosing to render them replication incompetent. Invossa^®-K polarizes macrophage to M2 macrophage. M2 macrophage has an immune-regulatory function by producing Interleukin-10. Therefore, Invossa^®-K reduces pain and improves the articular immune environment to contribute to self-recovery of an articular joint.

About Kolon Life Science

Kolon Life Science has been developing innovative cell and gene therapies including Invossa^®-K the world’s first cell-mediated gene therapy for osteoarthritis, since its founding in 2000. In addition to its biopharmaceuticals business, the company is also engaged in the business of providing active pharmaceuticals ingredients (API), eco-chemicals including antimicrobials for personal-care and industrial applications, as well as water-treatment solutions. For more information, please visit www.kolonls.co.kr/eng.

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg

SINGAPORE, June 26, 2018 /PRNewswire/ — Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to market Invossa^®-K in Saudi Arabia and United Arab Emirates. Invossa^®-K is a treatment for osteoarthritis pain with long-term efficacy. The agreement builds on the existing co-promotion agreement between the two companies in Korea signed in April 2017.

First approved by the Korean Ministry of Food and Drug Safety (MFDS) in 2017, the treatment has been hailed as the world’s first cell-mediated gene therapy for osteoarthritis.¹ Invossa^®-K is an intra-articular injection that is non-surgical treatment option, demonstrating sustained pain reduction and functional improvement of articular joint for two years following a single injection in a US phase II clinical trial and one year in a Korean phase III clinical trial.^2,3

Under the terms of the partnership, Mundipharma will be responsible for the marketing and distribution of Invossa^®-K to medical professionals and hospitals in Saudi Arabia and United Arab Emirates.

“We are delighted to extend our relationship with Kolon Life Science and Invossa^®-K internationally,” said Raman Singh, CEO, Mundipharma. “This partnership is a prime example of how our partners can effectively leverage the strength of our network capability and experience to ensure that hospitals, GPs and patients in new markets like Saudi Arabia and United Arab Emirates have access to new breakthrough treatments like Invossa^®-K,” he added.

The Osteoarthritis Research Society International (OARSI) defines osteoarthritis (OA) as ‘a disorder involving movable joints characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses including pro-inflammatory pathways of innate immunity.’⁴

“Mundipharma’s global sales and marketing capability in the area of pain management makes it an ideal partner to establish successful pathways into new markets,” said Woo-Sok Lee, President and CEO, Kolon Life Sciences. “They are an ideal partner to help establish Invossa^®-K in Saudi and UAE markets as we look to scale this breakthrough therapy as a global standard treatment option.”

®: INVOSSA is a Registered Trademark in Korea of Kolon TissueGene, Inc.

About Invossa^®-K

Invossa^®-K is composed of a 3:1 mixture of normal human chondrocytes (hChonJ) and human chondrocytes transduced with the human TGF-β1 gene (hChonJb#7). The hChonJb#7 cells are irradiated prior to dosing to render them replication incompetent. Invossa^®-K polarizes macrophage to M2 macrophage. M2 macrophage has an immune-regulatory function by producing Interleukin-10. Therefore, Invossa^®-K reduces pain and improves the articular immune environment to contribute to self-recovery of an articular joint.

About Kolon Life Science

Kolon Life Science has been developing innovative cell and gene therapies including Invossa^®-K the world’s first cell-mediated gene therapy for osteoarthritis, since its founding in 2000. In addition to its biopharmaceuticals business, the company is also engaged in the business of providing active pharmaceuticals ingredients (API), eco-chemicals including antimicrobials for personal-care and industrial applications, as well as water-treatment solutions. For more information, please visit www.kolonls.co.kr/eng.

About Mundipharma

Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg

Collaboration combines the power of the cloud with cutting-edge technologies such as AI and data to provide actionable insights for marketers in a mobile world

SAN FRANCISCO and REDMOND, Washington, June 26, 2018 /PRNewswire/ — InMobi, a global provider of enterprise platforms for marketers, today announced a strategic partnership with Microsoft Corp. to enable new-age CMOs in their transformational journey from digital to mobile marketing. The partnership will consist of InMobi moving to Microsoft Azure as its preferred cloud provider, and will involve technology collaboration and combined go-to-market strategies aimed at accelerating the way marketers are looking at their advertising and marketing strategies in an always-connected world.

Simultaneously, InMobi is significantly expanding its platform for marketers via the InMobi Marketing Cloud, adding to its decade-long market leadership through InMobi’s Advertising Cloud. The Marketing Cloud will enable marketers to get a 360-degree view of every customer, uncovering insights that help them design customer journeys for engagement, action and measurement, and analyzing and acting on customer feedback from disparate channels to increase retention and lifetime value of customers, while remaining committed toward the privacy rights of the customer.

“As digital technology is transforming every industry and every aspect of our lives, companies are seeking new ways to engage customers where they are, with connected, personalized experiences,” said Satya Nadella, CEO, Microsoft. “The combination of Microsoft Azure with InMobi’s marketing platforms will deliver new intelligent customer experiences and business insights to organizations around the world.”

With this partnership, InMobi will move in a phased manner to Microsoft Azure as its preferred cloud provider and tap into the power of its intelligent capabilities. With more regions than any other cloud provider, Microsoft Azure provides the global scale and trusted platform to meet the needs of the marketing industry.

There has been a fundamental shift in the advertising and marketing industry, with far more advanced technologies available to marketers, combined with an exponential increase in customer touchpoints across multiple connected devices. InMobi, with its new AI-powered Marketing Cloud, is at the forefront of these changes and evolving beyond its pure-play advertising platform to a comprehensive and integrated suite of advertising and marketing platforms.

“InMobi is building one of the most advanced enterprise platforms for marketers, and we’re extremely excited to partner with Microsoft as we dive into the next frontier of connected devices,” said Naveen Tewari, founder and CEO, InMobi. “With Microsoft’s global reach and advanced security, privacy and compliance, alongside InMobi’s scale and decade-long experience in mobile-first technology, we can truly disrupt the marketing ecosystem. Together, Microsoft and InMobi will create a formidable force in the industry.”

The two companies are also looking at additional opportunities in combining the power of InMobi’s Advertising and Marketing Cloud capabilities with Microsoft Dynamics 365 on the back of the global Azure infrastructure, including AI, machine learning and analytics. The companies will also work in close cooperation on the go-to-market approach, offering these integrated advertising and marketing solutions to Microsoft’s global enterprise client base.

The InMobi Marketing Cloud will be sequentially launched market-wise worldwide over the next six months.

About Microsoft
Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

About InMobi
InMobi is a global provider of enterprise platforms for marketers. As a leading technology company, InMobi has been recognized as a 2018 CNBC Disruptor 50 company and as one of Fast Company’s 2018 Most Innovative Companies. For more information, visit inmobi.com.

For more information, press only:
Microsoft Media Relations, WE Communications for Microsoft, (425) 638-7777,
rrt@we-worldwide.com

InMobi Media Relations
pr@inmobi.com

Photo – https://mma.prnewswire.com/media/710952/Satya_Naveen_Peggy_GroupPhoto1_lores.jpg
Logo – https://mma.prnewswire.com/media/266030/inmobi_logo.jpg